Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
17 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Jaguar Health, Inc.’s names, not what it holds today.
Patents granted
17
17 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 1 in 2023
Applications published
20
since 2001, to Dec 31, 2025
Names they are printed under
5
a subsidiary, a former name, its own name
By yearGrantedApplications published
'08'09'11'12'13'14'15'16'17'18'20'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
NAPO PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent
5 publishedNAPO PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
8 publishedJaguar Animal Health, Inc. a former name
named as the applicant on its applications, in US
3 publishedJAGUAR HEALTH, INC. its own name
named as the applicant on its applications, in US
2 publishedJaguar Animal Health, Inc. a former name
US, as the owner printed on each patent
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jan 2, 2024 | 11,857,510 | Methods and compositions for treating congenital diarrhea disorder | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Oct 10, 2023 | 11,779,564 | Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Jul 19, 2022 | 11,389,424 | Methods and compositions for treating chemotherapy-induced diarrhea | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Jun 5, 2018 | 9,987,250 | Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| May 29, 2018 | 9,980,938 | Method for treatment of diarrhea-predominant irritable bowel syndrome | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Mar 7, 2017 | 9,585,868 | Methods and compositions for treating HIV-associated diarrhea | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Apr 19, 2016 | 9,314,437 | Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (NDGA) | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Dec 1, 2015 | 9,198,879 | Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (NDGA) | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Sep 22, 2015 | 9,138,450 | Method for treatment of constipation-predominant irritable bowel syndrome | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Feb 24, 2015 | 8,962,680 | Methods and compositions for treating HIV-associated diarrhea | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 26, 2024 | 2024/0425514 | ALSTONINE DERIVATIVES AND SALTS THEREOF | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Oct 3, 2024 | 2024/0325346 | METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Jun 27, 2024 | 2024/0208988 | Alstonine Derivatives and Salts Thereof | Organic fine chemistry | NAPO PHARMACEUTICALS, INC. |
| Nov 17, 2022 | 2022/0362209 | METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. |
| Nov 5, 2020 | 2020/0345687 | METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. · patent 11,389,424 granted from it |
| Apr 23, 2020 | 2020/0121636 | METHODS AND COMPOSITIONS FOR TREATING BILE ACID DIARRHEA, DIARRHEA ASSOCIATED WITH SMALL INTESTINE RESECTION OR GALLBLADDER REMOVAL, AND SHORT BOWEL SYNDROME | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. · patent 11,779,564 granted from it |
| Apr 9, 2020 | 2020/0108047 | METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER | Pharmaceuticals | NAPO PHARMACEUTICALS, INC. · patent 11,857,510 granted from it |
| Sep 20, 2018 | 2018/0264061 | Methods of Treating Diarrhea in Companion Animals | Pharmaceuticals | Jaguar Animal Health, Inc. |
| Feb 1, 2018 | 2018/0028490 | Methods Of Treating Diarrhea And Promoting Intestinal Health In Non-Human Animals | Pharmaceuticals | JAGUAR HEALTH, INC. |
| Jan 25, 2018 | 2018/0021297 | Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animals | Pharmaceuticals | JAGUAR HEALTH, INC. |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.